[Evaluation of astemizole in allergic conjunctivitis]

A 4 week open study was carried out to evaluate the efficacy and safety of astemizole in the treatment of allergic conjunctivitis 31 patients were included in the study. Global efficacy, with 10 mg astemizole OD, was rated good or excellent in 100% of treated patients. A marked improvement of the main symptoms was noted at day 15. No side effects whether of the anticholinergic type or of the drowsiness type, were observed during the whole study. Astemizole appears to be a particularly interesting symptomatic treatment of allergic conjunctivitis.